| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/22/2001 | WO2001012128A2 Antibacterial agents for the treatment of acute mucosal infections |
| 02/22/2001 | WO2001012103A1 Metering and packaging of controlled release medication |
| 02/22/2001 | WO2000078941A3 Methods and products for manipulating uncoupling protein expression |
| 02/22/2001 | WO2000077246A3 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| 02/22/2001 | WO2000077179A3 Human poly(adp-ribose) polymerase 2 materials and methods |
| 02/22/2001 | WO2000074677A3 Improved pharmaceutical formulations |
| 02/22/2001 | WO2000073330A3 Method and compositions relating to insulin resistance disorders |
| 02/22/2001 | WO2000072863A3 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 02/22/2001 | WO2000072008A3 Identification of novel mechanisms of drug resistance |
| 02/22/2001 | WO2000057853A3 Pharmaceutical composition containing an extrusion additive |
| 02/22/2001 | WO2000055633A3 Methods of screening for colorectal cancer modulators |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO2000040614A3 Characterization of the soc/crac calcium channel protein family |
| 02/22/2001 | WO2000023100A8 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 02/22/2001 | WO2000023065A8 Storable active substance concentrate with formoterol |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | WO1999047553A3 Bacterial yeal family members as targets for antimicrobial drug design |
| 02/22/2001 | WO1999046279A3 INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 02/22/2001 | DE19940220A1 Preparation for treating rheumatic joint diseases, e.g. arthritis, comprising injectable, induction heatable, iron oxide-based magnetic particles including radionuclide and cytotoxic agent |
| 02/22/2001 | DE19938823A1 Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol |
| 02/22/2001 | CA2464845A1 Hematopoietic regulatory factors and methods of use thereof |
| 02/22/2001 | CA2414171A1 Partial agonists at the glycine modulatory site of the nmda receptor for treating cognitive dysfunction |
| 02/22/2001 | CA2383922A1 Cytokine receptor common gamma chain like |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2382251A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2382015A1 Membrane associated proteins |
| 02/22/2001 | CA2381979A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | CA2381978A1 Ppar.delta. links apc to chemopreventive drugs |
| 02/22/2001 | CA2381780A1 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 02/22/2001 | CA2381706A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | CA2381700A1 Method for identifying modulating compounds of neurotransmitters |
| 02/22/2001 | CA2380983A1 Methods for identification of compounds stimulating insulin secretion |
| 02/22/2001 | CA2380979A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | CA2380966A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | CA2380953A1 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 02/22/2001 | CA2380892A1 Formation of nanometer-scale structures |
| 02/22/2001 | CA2380888A1 Treatment of metastatic disease |
| 02/22/2001 | CA2380883A1 Microparticles for pulmonary administration |
| 02/22/2001 | CA2380820A1 Neurotherapeutic clavulanate composition and method |
| 02/22/2001 | CA2380753A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | CA2380643A1 Topical organic ectoparasiticidal formulations |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380596A1 Metering and packaging of controlled release medication |
| 02/22/2001 | CA2380432A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | CA2380373A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | CA2377662A1 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | CA2377133A1 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| 02/21/2001 | EP1077070A2 Oral drug delivery compositions |
| 02/21/2001 | EP1076723A2 Use of cathepsin s in the diagnosis and treatment of endometriosis |
| 02/21/2001 | EP1076711A2 Human apoptosis associated proteins |
| 02/21/2001 | EP1076703A2 Il-17 homologous polypeptides and therapeutic uses thereof |
| 02/21/2001 | EP1076702A1 Human protease associated proteins |
| 02/21/2001 | EP1076696A2 Human receptor molecules |
| 02/21/2001 | EP1076691A1 Cellular and animal models for diseases associated with altered mitochondrial function |
| 02/21/2001 | EP1076569A1 Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| 02/21/2001 | EP1076562A1 Glucocorticoid receptor antagonists for the treatment of dementia |
| 02/21/2001 | EP1076561A2 Combination therapy for the treatment of tumors |
| 02/21/2001 | EP0871470A4 Haemopoietic growth factor antagonists and uses therefor |
| 02/21/2001 | CN1285003A Screening appays for the detection and diagnosis of influenza virus |
| 02/21/2001 | CN1285001A Methods for simultaneous identification of novel biological targets and lead structures for drug development |
| 02/21/2001 | CN1284997A Modified deacetoxycephalosporin C synthase (DAOCS) and x-ray structure |
| 02/21/2001 | CN1284875A Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
| 02/21/2001 | CN1284868A Oral pharmaceutical pulsed release dosage form |
| 02/21/2001 | CN1284325A Composition for treating scurf, psoriasis and eczema |
| 02/21/2001 | CN1062182C Novel physiologically active substance |
| 02/20/2001 | US6191261 Immunoglobulin that preferential binds a growth factor; for the diagnosis and treatment of cell proliferative defects; antiproliferative agents |
| 02/20/2001 | US6191156 Compositions and methods for treating bladder dysfunction |
| 02/20/2001 | US6191154 Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| 02/20/2001 | US6191139 Antidepressant |
| 02/20/2001 | US6191132 Use of quisqualate receptor antagonists |
| 02/20/2001 | US6191126 Topical administering |
| 02/20/2001 | US6191125 Small molecule pipecolic acid derivative hair growth compositions and uses |
| 02/20/2001 | US6191119 Synergistic mixture with doxorubicin; antiproliferative agent |
| 02/20/2001 | US6191112 Human therapeutic uses of BPI protein products |
| 02/20/2001 | US6190909 TH2-specific gene |
| 02/20/2001 | US6190894 Method and compositions for disrupting the epithelial barrier function |
| 02/20/2001 | US6190693 Administering pharmaceutical formulation comprising hormonal replacememt for treating or preventing menopausal condition and folic acid |
| 02/20/2001 | US6190667 Contacting parental helicobacter strain with molecule in biological sample and contacting helicobacter strain deficient in urei gene with molecule; comparing acidity sensitivity of both strains; selecting molecule that increases acidity |
| 02/20/2001 | CA2302629C Estrogen receptor |
| 02/20/2001 | CA2122519C Cancer treatment and metastasis prevention |
| 02/15/2001 | WO2001011369A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 02/15/2001 | WO2001011086A2 Methods of screening for angiogenesis modulators |
| 02/15/2001 | WO2001011054A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 02/15/2001 | WO2001011050A1 Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY |
| 02/15/2001 | WO2001011046A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | WO2001011027A1 New protein |
| 02/15/2001 | WO2001010906A1 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 02/15/2001 | WO2001010904A1 Map |
| 02/15/2001 | WO2001010903A2 Proteases and protease inhibitors |
| 02/15/2001 | WO2001010900A2 Globular assembly of amyloid beta protein and uses thereof |
| 02/15/2001 | WO2001010867A1 Vitronectin receptor antagonists useful for the treatment of strokes |
| 02/15/2001 | WO2001010838A1 Multivalent compounds |
| 02/15/2001 | WO2001010468A2 Drug-carrier complexes and methods of use thereof |
| 02/15/2001 | WO2001010458A1 Use of neurotoxin for treating cardiac muscle disorders |
| 02/15/2001 | WO2001010456A2 Peptides that block viral infectivity and methods of use thereof |
| 02/15/2001 | WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | WO2001010454A2 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
| 02/15/2001 | WO2001010446A2 Formulations for parenteral use of estramustine phosphate and albumin |